DSG4.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
14
+[[include:table1_DSG4.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
DSP.md
... ...
@@ -13,10 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
19
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established|
16
+[[include:table1_DSP.md]]
20 17
21 18
22 19
DTNB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established|
16
+[[include:table1_DTNB.md]]
19 17
20 18
21 19
DTX1.md
... ...
@@ -14,13 +14,7 @@ Mutations in the DTX1 gene, which encodes the E3 ubiquitin ligase Deltex 1, have
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@gomezUltraDeepSequencingReveals2023]|
20
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
21
-|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @schmitzGeneticsPathogenesisDiffuse2018; @chapuyMolecularSubtypesDiffuse2018]|
23
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
17
+[[include:table1_DTX1.md]]
24 18
25 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 20
DTX3L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_DTX3L.md]]
19 17
20 18
21 19
DUOXA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DUOXA2.md]]
19 17
20 18
21 19
DUPD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DUPD1.md]]
19 17
20 18
21 19
DUSP2.md
... ...
@@ -19,11 +19,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva
19 19
20 20
## Relevance tier by entity
21 21
22
-|Entity|Tier|Description |
23
-|:------:|:----:|--------------------------------------|
24
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021]|
25
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @lohrDiscoveryPrioritizationSomatic2012]|
26
-|![FL](images/icons/FL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous |
22
+[[include:table1_DUSP2.md]]
27 23
28 24
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
29 25
DUSP27.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_DUSP27.md]]
19 17
20 18
21 19
DUSP9.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_DUSP9.md]]
19 17
20 18
21 19
DYNC1H1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DYNC1H1.md]]
19 17
20 18
21 19
DYNC1I1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_DYNC1I1.md]]
19 17
20 18
21 19
E2F2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
14
+[[include:table1_E2F2.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
EBF1.md
... ...
@@ -15,12 +15,7 @@ EBF1 is a critical transcription factor in early B-cell development, regulating
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@bohleRoleEarlyBcell2013; @albuquerqueEnhancingKnowledgeDiscovery2017; @morinMutationalStructuralAnalysis2013]|
22
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
23
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@thomasGeneticSubgroupsInform2023]|
18
+[[include:table1_EBF1.md]]
24 19
25 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 21
ECGF1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ECGF1.md]]
19 17
20 18
21 19
ECT2L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_ECT2L.md]]
19 17
20 18
21 19
EDNRB.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
14
+[[include:table1_EDNRB.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
EEF1A1.md
... ...
@@ -15,11 +15,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@hubschmannMutationalMechanismsShaping2021]|
22
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@hubschmannMutationalMechanismsShaping2021]|
18
+[[include:table1_EEF1A1.md]]
23 19
24 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 21
EGFR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_EGFR.md]]
19 17
20 18
21 19
EGR1.md
... ...
@@ -13,11 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
19
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
20
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_EGR1.md]]
21 17
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EGR2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
+[[include:table1_EGR2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EHD1.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|--------------------------------------|
14
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@thomasGeneticSubgroupsInform2023]|
12
+[[include:table1_EHD1.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
EIF2AK3.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
12
+[[include:table1_EIF2AK3.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
EIF2AK4.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_EIF2AK4.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
EIF2C4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |2 | Failed QC[@loveGeneticLandscapeMutations2012]|
16
+[[include:table1_EIF2C4.md]]
19 17
20 18
## Warnings
21 19
EIF4A1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------|
16
-|![BL](images/icons/BL_tier1.png) |2 |low-confidence BL gene[@paneaWholeGenomeLandscape2019]|
14
+[[include:table1_EIF4A1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
ELP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png)|2|relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
16
+[[include:table1_ELP2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EML2.md
... ...
@@ -17,9 +17,7 @@ Due to [minimal support](EML2#representative-mutation) in the original primary d
17 17
18 18
## Relevance tier by entity
19 19
20
-|Entity|Tier|Description |
21
-|:------:|:----:|--------------------------------------|
22
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
20
+[[include:table1_EML2.md]]
23 21
24 22
## Warnings
25 23
ENTPD3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
16
+[[include:table1_ENTPD3.md]]
19 17
20 18
## Warnings
21 19
EP300.md
... ...
@@ -18,11 +18,7 @@ Studies using genome-wide CRISPR-Cas9 screens have identified synthetic lethal i
18 18
19 19
## Relevance tier by entity
20 20
21
-|Entity|Tier|Description |
22
-|:------:|:----:|--------------------------------------|
23
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
24
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011]|
25
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene supported by functional data [@pasqualucciInactivatingMutationsAcetyltransferase2011]|
21
+[[include:table1_EP300.md]]
26 22
27 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 24
EPHA3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_EPHA3.md]]
19 17
20 18
21 19
EPHA5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_EPHA5.md]]
19 17
20 18
21 19
EPHA7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_EPHA7.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EPPK1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------|
16
-|![BL](images/icons/BL_tier1.png) |2 |low-confidence BL gene[@paneaWholeGenomeLandscape2019]|
14
+[[include:table1_EPPK1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
ERAP1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
14
+[[include:table1_ERAP1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
ERAP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@albuquerqueEnhancingKnowledgeDiscovery2017]|
16
+[[include:table1_ERAP2.md]]
19 17
20 18
21 19
ERBB3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ERBB3.md]]
19 17
20 18
21 19
ERN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ERN2.md]]
19 17
20 18
21 19
ESX1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_ESX1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
ETNPPL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ETNPPL.md]]
19 17
20 18
21 19
ETS1.md
... ...
@@ -18,11 +18,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva
18 18
19 19
## Relevance tier by entity
20 20
21
-|Entity|Tier|Description |
22
-|:------:|:----:|--------------------------------------|
23
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
24
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
25
-|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
21
+[[include:table1_ETS1.md]]
26 22
27 23
## Warnings
28 24
ETV6.md
... ...
@@ -18,9 +18,7 @@ Coding and non-coding mutations in this gene are associated with the MCD genetic
18 18
19 19
## Relevance tier by entity
20 20
21
-|Entity|Tier|Description |
22
-|:------:|:----:|--------------------------|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012; @albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017]|
21
+[[include:table1_ETV6.md]]
24 22
25 23
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 24
EWSR1.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@pararajalingamCodingNoncodingDrivers2020]|
13
+[[include:table1_EWSR1.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
EXOSC6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_EXOSC6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
EXTL3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_EXTL3.md]]
19 17
20 18
21 19
EZH1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_EZH1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
EZR.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
14
+[[include:table1_EZR.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
FAIM.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FAIM.md]]
19 17
20 18
21 19
FAM129B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
16
+[[include:table1_FAM129B.md]]
19 17
20 18
## Warnings
21 19
FAM161A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FAM161A.md]]
19 17
20 18
21 19
FAM38B.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
14
+[[include:table1_FAM38B.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
FAM62C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FAM62C.md]]
19 17
20 18
21 19
FANCD2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FANCD2.md]]
19 17
20 18
21 19
FAS.md
... ...
@@ -17,12 +17,7 @@ In mouse models, Fas mutations led to a significantly shorter lymphoma-specific
17 17
18 18
## Relevance tier by entity
19 19
20
-|Entity|Tier|Description |
21
-|:------:|:----:|--------------------------------------|
22
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
23
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
24
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@schollMutationsRegionFAS2007]|
25
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
20
+[[include:table1_FAS.md]]
26 21
27 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 23
FAT2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@morinFrequentMutationHistonemodifying2011]|
16
+[[include:table1_FAT2.md]]
19 17
20 18
21 19
FAT4.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
18
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established [@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_FAT4.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
FBLN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_FBLN2.md]]
19 17
20 18
21 19
FBXO31.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_FBXO31.md]]
19 17
20 18
21 19
FBXW7.md
... ...
@@ -16,9 +16,7 @@ In leukemias, FBXW7 mutations enhance the activity of leukemia-initiating cells
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|
19
+[[include:table1_FBXW7.md]]
22 20
23 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 22
FGD3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FGD3.md]]
19 17
20 18
21 19
FGFR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FGFR1.md]]
19 17
20 18
21 19
FGFR3.md
... ...
@@ -16,9 +16,7 @@ Due to [minimal support](FGFR3#representative-mutation) in the original primary
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
19
+[[include:table1_FGFR3.md]]
22 20
23 21
## Warnings
24 22
FGFRL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_FGFRL1.md]]
19 17
20 18
21 19
FIGN.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FIGN.md]]
19 17
20 18
21 19
FLNA.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FLNA.md]]
19 17
20 18
21 19
FLNC.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FLNC.md]]
19 17
20 18
21 19
FLT1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FLT1.md]]
19 17
20 18
21 19
FLYWCH1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_FLYWCH1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
FMO2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FMO2.md]]
19 17
20 18
21 19
FN1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FN1.md]]
19 17
20 18
21 19
FNDC1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_FNDC1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
FOXC1.md
... ...
@@ -12,9 +12,7 @@ FOXC1 is a transcription factor that regulates genes involved in cell growth, di
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
15
+[[include:table1_FOXC1.md]]
18 16
19 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 18
FOXP1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_FOXP1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
FRMPD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_FRMPD1.md]]
19 17
20 18
21 19
FTCD.md
... ...
@@ -19,9 +19,7 @@ Due to [minimal support](FTCD#representative-mutation) in the original primary d
19 19
20 20
## Relevance tier by entity
21 21
22
-|Entity|Tier|Description |
23
-|:------:|:----:|--------------------------------------|
24
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
22
+[[include:table1_FTCD.md]]
25 23
26 24
## Warnings
27 25
FUBP1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_FUBP1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
FUT5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_FUT5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
FZD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_FZD1.md]]
19 17
20 18
21 19
FZD3.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_FZD3.md]]
18 16
19 17
## Warnings
20 18
FZR1.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_FZR1.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
GABRA1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_GABRA1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GABRA2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_GABRA2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GABRG1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GABRG1.md]]
19 17
20 18
21 19
GAK.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_GAK.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
GATA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_GATA2.md]]
19 17
20 18
21 19
GATA3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_GATA3.md]]
19 17
20 18
21 19
GBP7.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_GBP7.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GCN1L1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GCN1L1.md]]
19 17
20 18
21 19
GCSAM.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_GCSAM.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GGTLA4.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_GGTLA4.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
GJA8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GJA8.md]]
19 17
20 18
21 19
GJB4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GJB4.md]]
19 17
20 18
21 19
GNAS.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_GNAS.md]]
17 15
18 16
## Warnings
19 17
GOLGA5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_GOLGA5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GOPC.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GOPC.md]]
19 17
20 18
21 19
GPC5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_GPC5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GPD2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GPD2.md]]
19 17
20 18
21 19
GPR126.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wenigerMutationsTumorSuppressor2006]|
16
+[[include:table1_GPR126.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GPR133.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GPR133.md]]
19 17
20 18
21 19
GPR15.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GPR15.md]]
19 17
20 18
21 19
GPR98.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_GPR98.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GPS2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
+[[include:table1_GPS2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
GRB2.md
... ...
@@ -16,9 +16,7 @@ Further research is needed to elucidate its specific role in DLBCL.
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@pasqualucciAnalysisCodingGenome2011]|
19
+[[include:table1_GRB2.md]]
22 20
23 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 22
GREM2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GREM2.md]]
19 17
20 18
21 19
GRHPR.md
... ...
@@ -13,9 +13,7 @@ GRHPR is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@arthurGenomewideDiscoverySomatic2018]|
16
+[[include:table1_GRHPR.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
GRIA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GRIA2.md]]
19 17
20 18
21 19
GRIK5.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_GRIK5.md]]
17 15
18 16
## Warnings
19 17
GRIN2A.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_GRIN2A.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GRM5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_GRM5.md]]
19 17
20 18
21 19
GRM6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_GRM6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GSG2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_GSG2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
GTSE1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_GTSE1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
H1-4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
16
+[[include:table1_H1-4.md]]
19 17
20 18
21 19
H1-5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
16
+[[include:table1_H1-5.md]]
19 17
20 18
21 19
H1FOO.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_H1FOO.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
H6PD.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_H6PD.md]]
19 17
20 18
21 19
HACE1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HACE1.md]]
19 17
20 18
21 19
HCK.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HCK.md]]
19 17
20 18
21 19
HDAC7.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_HDAC7.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HECW2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_HECW2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HELLS.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_HELLS.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HEPH.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_HEPH.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HERC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_HERC2.md]]
19 17
20 18
21 19
HFE.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_HFE.md]]
19 17
20 18
21 19
HIPK3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HIPK3.md]]
19 17
20 18
21 19
HIST1H1B.md
... ...
@@ -13,11 +13,7 @@ This is one of several genes that encode linker histone proteins that are recurr
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018]|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
16
+[[include:table1_HIST1H1B.md]]
21 17
22 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 19
HIST1H1C.md
... ...
@@ -15,12 +15,7 @@ This is one of several genes that encode linker histone proteins that are recurr
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
22
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
23
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]]|
18
+[[include:table1_HIST1H1C.md]]
24 19
25 20
## Warnings
26 21
HIST1H1D.md
... ...
@@ -14,12 +14,7 @@ Mutations are often found in the globular domain of the protein, which is critic
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
20
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018]|
22
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
17
+[[include:table1_HIST1H1D.md]]
23 18
24 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 20
HIST1H2AC.md
... ...
@@ -14,10 +14,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @chapuyMolecularSubtypesDiffuse2018; @hubschmannMutationalMechanismsShaping2021]|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
17
+[[include:table1_HIST1H2AC.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
HIST1H2AD.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_HIST1H2AD.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H2AG.md
... ...
@@ -13,12 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|-----------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
19
-|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
21
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
16
+[[include:table1_HIST1H2AG.md]]
22 17
23 18
## Warnings
24 19
HIST1H2AL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_HIST1H2AL.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H2AM.md
... ...
@@ -16,11 +16,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
22
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
23
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
19
+[[include:table1_HIST1H2AM.md]]
24 20
25 21
## Warnings
26 22
HIST1H2BC.md
... ...
@@ -13,11 +13,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
16
+[[include:table1_HIST1H2BC.md]]
21 17
22 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 19
HIST1H2BD.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------|
15
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_HIST1H2BD.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HIST1H2BG.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------|
15
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_HIST1H2BG.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HIST1H2BK.md
... ...
@@ -16,11 +16,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
22
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @chapuyMolecularSubtypesDiffuse2018]|
19
+[[include:table1_HIST1H2BK.md]]
24 20
25 21
## Warnings
26 22
HIST1H2BM.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_HIST1H2BM.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HIST1H2BO.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_HIST1H2BO.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H3A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_HIST1H3A.md]]
19 17
20 18
21 19
HIST1H3B.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
17
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
13
+[[include:table1_HIST1H3B.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
HIST1H3D.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_HIST1H3D.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HIST1H3G.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------|
15
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_HIST1H3G.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HIST1H3H.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
14
+[[include:table1_HIST1H3H.md]]
17 15
18 16
## Warnings
19 17
HIST1H3I.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_HIST1H3I.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
HIST1H3J.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
16
+[[include:table1_HIST1H3J.md]]
19 17
20 18
## Warnings
21 19
HIST1H4E.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_HIST1H4E.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HIST1H4I.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HIST1H4I.md]]
19 17
20 18
21 19
HIST1H4J.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_HIST1H4J.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
HIST2H2BE.md
... ...
@@ -13,9 +13,7 @@ This gene encodes the H2A protein, one of the core proteins comprising nucleosom
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
16
+[[include:table1_HIST2H2BE.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
HIST4H4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_HIST4H4.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HK3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HK3.md]]
19 17
20 18
21 19
HLA-A.md
... ...
@@ -14,10 +14,7 @@ Mutations in the HLA-B gene have been associated with a loss of cell surface exp
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]|
17
+[[include:table1_HLA-A.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
HLA-B.md
... ...
@@ -14,11 +14,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012]|
21
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
17
+[[include:table1_HLA-B.md]]
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 20
HLA-C.md
... ...
@@ -15,10 +15,7 @@ The mutation pattern in DLBCL implies the preferential accumulation of *inactiva
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------|
20
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene|
18
+[[include:table1_HLA-C.md]]
22 19
23 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 21
HLA-DMA.md
... ...
@@ -12,9 +12,7 @@ Mutations in this gene are relatively rare in DLBCL overall.
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |Association with DLBCL is tenuous|
15
+[[include:table1_HLA-DMA.md]]
18 16
19 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 18
HLA-DMB.md
... ...
@@ -12,9 +12,7 @@ HLA-DMB, along with HLA-DMA, plays a critical role in the proper functioning of
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
15
+[[include:table1_HLA-DMB.md]]
18 16
19 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 18
HLA-DQA1.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@hubschmannMutationalMechanismsShaping2021]|
18
+[[include:table1_HLA-DQA1.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
HLA-DQB1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_HLA-DQB1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HLA-DRB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_HLA-DRB1.md]]
19 17
20 18
21 19
HMGB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_HMGB1.md]]
19 17
20 18
21 19
HNF1B.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
13
+[[include:table1_HNF1B.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
HNRNPD.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
16
+[[include:table1_HNRNPD.md]]
19 17
20 18
21 19
HNRNPH1.md
... ...
@@ -16,10 +16,7 @@ The common HNRNPH1 mutations cause deregulated splicing and increased expression
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |high-confidence DLBCL gene[@pararajalingamCodingNoncodingDrivers2020]|
22
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@pararajalingamCodingNoncodingDrivers2020]|
19
+[[include:table1_HNRNPH1.md]]
23 20
24 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 22
HNRNPR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HNRNPR.md]]
19 17
20 18
21 19
HRAS.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_HRAS.md]]
18 15
19 16
## Warnings
20 17
HRNR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
16
+[[include:table1_HRNR.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
HSF2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_HSF2.md]]
19 17
20 18
21 19
HVCN1.md
... ...
@@ -13,10 +13,7 @@ HVCN1, a voltage-gated proton channel, has been identified as recurrently mutate
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
19
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
16
+[[include:table1_HVCN1.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
ICK.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_ICK.md]]
17 15
18 16
## arnings
19 17
IDH1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_IDH1.md]]
19 17
20 18
21 19
IER2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_IER2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
IFNGR1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_IFNGR1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
IKBKB.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wienandGenomicAnalysesFlowsorted2019]|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiAlterationBIRC3Multiple2011]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_IKBKB.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
IKBKE.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_IKBKE.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
IKZF3.md
... ...
@@ -13,10 +13,7 @@ IKZF3 (IKAROS family zinc finger 3, also known as AIOLOS) is a transcription fac
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinMutationalStructuralAnalysis2013]|
16
+[[include:table1_IKZF3.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
IL13RA1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_IL13RA1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
IL16.md
... ...
@@ -12,9 +12,7 @@ The IL16 gene, which encodes a pro-inflammatory cytokine, plays a role in immune
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene|
15
+[[include:table1_IL16.md]]
18 16
19 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 18
IL1RAPL2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_IL1RAPL2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
IL4R.md
... ...
@@ -13,10 +13,7 @@ Mutations in IL4R have been identified in various types of B-cell lymphomas, par
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@viganoSomaticIL4RMutations2018]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@dunsCharacterizationDLBCLPMBL2021]|
16
+[[include:table1_IL4R.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
IL6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_IL6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
IL6ST.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_IL6ST.md]]
19 17
20 18
21 19
INO80.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
17
+[[include:table1_INO80.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
INSC.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_INSC.md]]
19 17
20 18
21 19
INTS6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_INTS6.md]]
19 17
20 18
21 19
IQGAP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_IQGAP1.md]]
19 17
20 18
21 19
IQUB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_IQUB.md]]
19 17
20 18
21 19
IRF1.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_IRF1.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
IRF2BP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_IRF2BP2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
IRF4.md
... ...
@@ -16,11 +16,7 @@ There are a few mutation hotspots in this gene. The functional role of mutations
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011]|
23
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
19
+[[include:table1_IRF4.md]]
24 20
25 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 22
IRF8.md
... ...
@@ -17,12 +17,7 @@ These are crucial for processing and presentation of self antigens.
17 17
18 18
## Relevance tier by entity
19 19
20
-|Entity|Tier|Description |
21
-|:------:|:----:|--------------------------------------|
22
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
23
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
24
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
25
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
20
+[[include:table1_IRF8.md]]
26 21
27 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 23
ITGA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ITGA2.md]]
19 17
20 18
21 19
ITGA8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ITGA8.md]]
19 17
20 18
21 19
ITGB3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ITGB3.md]]
19 17
20 18
21 19
ITGB4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_ITGB4.md]]
19 17
20 18
21 19
ITPKB.md
... ...
@@ -13,11 +13,7 @@ The ITPKB gene encodes inositol-trisphosphate 3-kinase B, an enzyme involved in
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
20
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
16
+[[include:table1_ITPKB.md]]
21 17
22 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 19
ITPR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_ITPR1.md]]
19 17
20 18
21 19
ITPR3.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_ITPR3.md]]
18 15
19 16
## Warnings
20 17
JAG1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_JAG1.md]]
19 17
20 18
21 19
JAK1.md
... ...
@@ -15,10 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
21
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
18
+[[include:table1_JAK1.md]]
22 19
23 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 21
JAK3.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
18
+[[include:table1_JAK3.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
JAKMIP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_JAKMIP2.md]]
19 17
20 18
21 19
JUNB.md
... ...
@@ -15,10 +15,7 @@ JUNB has been reported to be frequently mutated in T-cell/histiocyte-rich large
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------|
20
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|
18
+[[include:table1_JUNB.md]]
22 19
23 20
## Warnings
24 21
JUP.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_JUP.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
KANK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![BL](images/icons/BL_tier2.png)|2|relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
16
+[[include:table1_KANK2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KAT6A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_KAT6A.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KCMF1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_KCMF1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
KCNA3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KCNA3.md]]
19 17
20 18
21 19
KCNAB3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KCNAB3.md]]
19 17
20 18
21 19
KCNC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_KCNC2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KCNJ6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KCNJ6.md]]
19 17
20 18
21 19
KCNK10.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_KCNK10.md]]
18 16
19 17
## Warnings
20 18
KCNT2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KCNT2.md]]
19 17
20 18
21 19
KDM2B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_KDM2B.md]]
19 17
20 18
21 19
KDM6A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_KDM6A.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KDR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KDR.md]]
19 17
20 18
21 19
KIAA1614.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_KIAA1614.md]]
19 17
20 18
21 19
KIAA1671.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_KIAA1671.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KIF1C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_KIF1C.md]]
19 17
20 18
21 19
KIF21B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KIF21B.md]]
19 17
20 18
21 19
KIF26A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_KIF26A.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
KIFC3.md
... ...
@@ -14,9 +14,7 @@ Due to [minimal support](KIFC3#representative-mutations) in the original primary
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
17
+[[include:table1_KIFC3.md]]
20 18
21 19
## Warnings
22 20
KIR3DL1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_KIR3DL1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
KIT.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KIT.md]]
19 17
20 18
21 19
KITLG.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_KITLG.md]]
19 17
20 18
21 19
KLB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KLB.md]]
19 17
20 18
21 19
KLC3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KLC3.md]]
19 17
20 18
21 19
KLF2.md
... ...
@@ -16,12 +16,7 @@ Contradictory to this, the mutation pattern in DLBCL implies selective pressure
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@jalladesExomeSequencingIdentifies2017]|
22
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@pasqualucciAnalysisCodingGenome2011]|
24
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
19
+[[include:table1_KLF2.md]]
25 20
26 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
27 22
KLF4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KLF4.md]]
19 17
20 18
21 19
KLHL14.md
... ...
@@ -13,9 +13,7 @@ KLHL14 (Kelch-like family member 14) is a gene that has been identified as playi
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017; @schmitzGeneticsPathogenesisDiffuse2018]|
16
+[[include:table1_KLHL14.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
KLHL21.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_KLHL21.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
KLHL26.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_KLHL26.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
KLHL6.md
... ...
@@ -14,11 +14,7 @@ KLHL6 is considered a tumor suppressor gene in DLBCL with mutations tending to d
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@ganapathiGeneticLandscapeDural2016]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
21
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
17
+[[include:table1_KLHL6.md]]
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 20
KLRC4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_KLRC4.md]]
19 17
20 18
21 19
KMT2C.md
... ...
@@ -14,12 +14,7 @@ This gene has been reported to be recurrently mutated in DLBCL. The rate of muta
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|---------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]|
20
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established [@zhouSporadicEndemicBurkitt2019]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017]|
22
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
17
+[[include:table1_KMT2C.md]]
23 18
24 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 20
KRAS.md
... ...
@@ -13,9 +13,7 @@ KRAS mutations are rare but occur in some cases of DLBCL.[@lohrDiscoveryPrioriti
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_KRAS.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
KRT6A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_KRT6A.md]]
19 17
20 18
21 19
KRTAP5-5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_KRTAP5-5.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
LAMA5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_LAMA5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
LAPTM5.md
... ...
@@ -14,10 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
20
-|![FL](images/icons/FL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in FL is tenuous [@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_LAPTM5.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
LCOR.md
... ...
@@ -13,9 +13,7 @@ LCOR (Ligand Dependent Nuclear Receptor Corepressor) is involved in the regulati
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@arthurGenomewideDiscoverySomatic2018]|
16
+[[include:table1_LCOR.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
LEPR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_LEPR.md]]
19 17
20 18
21 19
LEPREL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LEPREL1.md]]
19 17
20 18
21 19
LIFR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LIFR.md]]
19 17
20 18
21 19
LILRA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LILRA2.md]]
19 17
20 18
21 19
LIMD2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|
16
+[[include:table1_LIMD2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
LIN54.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC|
14
+[[include:table1_LIN54.md]]
17 15
18 16
## Warnings
19 17
LIN7C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LIN7C.md]]
19 17
20 18
21 19
LPHN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LPHN2.md]]
19 17
20 18
21 19
LPHN3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
16
+[[include:table1_LPHN3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
LPP.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
14
+[[include:table1_LPP.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
LRAP.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LRAP.md]]
19 17
20 18
21 19
LRIG3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LRIG3.md]]
19 17
20 18
21 19
LRP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LRP1.md]]
19 17
20 18
21 19
LRP10.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LRP10.md]]
19 17
20 18
21 19
LRP12.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
18
+[[include:table1_LRP12.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
LRP1B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_LRP1B.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
LRP3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LRP3.md]]
19 17
20 18
21 19
LRRN3.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@sarkozyMutationalLandscapeGray2021]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |High-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_LRRN3.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
LTB.md
... ...
@@ -13,12 +13,7 @@ LTB (Lymphotoxin Beta) is a member of the tumor necrosis factor (TNF) superfamil
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@deschGenotypingCirculatingTumor2020]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@chapuyMolecularSubtypesDiffuse2018]|
20
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
21
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
16
+[[include:table1_LTB.md]]
22 17
23 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 19
LUZP4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_LUZP4.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
LYN.md
... ...
@@ -12,9 +12,7 @@ LYN mutations have been reported in DLBCL but the rate is relatively rare in mos
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |low-confidence DLBCL gene[@chapuyMolecularSubtypesDiffuse2018]|
15
+[[include:table1_LYN.md]]
18 16
19 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 18
LYST.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_LYST.md]]
19 17
20 18
21 19
MAGEC1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_MAGEC1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MAGEC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_MAGEC2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MAGEC3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_MAGEC3.md]]
19 17
20 18
21 19
MAGT1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_MAGT1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MALAT1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_MALAT1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MAP2K1.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@shinBRAFV600EMAP2K12015]|
16
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@louissaintPediatrictypeNodalFollicular2016]|
13
+[[include:table1_MAP2K1.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
MAP2K3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_MAP2K3.md]]
19 17
20 18
21 19
MAP3K14.md
... ...
@@ -13,10 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiAlterationBIRC3Multiple2011]|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@ottoGeneticLesionsTRAF32012]|
16
+[[include:table1_MAP3K14.md]]
20 17
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MAP3K6.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_MAP3K6.md]]
17 15
18 16
## Warnings
19 17
MAP4K4.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_MAP4K4.md]]
17 15
18 16
## Warnings
19 17
MAP7D1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_MAP7D1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MARCHF7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MARCHF7.md]]
19 17
20 18
21 19
MARK1.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|-----------------------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
15
+[[include:table1_MARK1.md]]
18 16
19 17
## Warnings
20 18
MBL2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MBL2.md]]
19 17
20 18
21 19
MCL1.md
... ...
@@ -15,11 +15,7 @@ MCL1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
21
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@reddyGeneticFunctionalDrivers2017]|
18
+[[include:table1_MCL1.md]]
23 19
24 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 21
MCM8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_MCM8.md]]
19 17
20 18
21 19
MCRS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
+[[include:table1_MCRS1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MECOM.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_MECOM.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MED12L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_MED12L.md]]
19 17
20 18
21 19
MED13L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MED13L.md]]
19 17
20 18
21 19
MEF2B.md
... ...
@@ -16,11 +16,7 @@ Thus far, there is limited information about the consequence of MEF2B mutations
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
23
-|![FL](images/icons/FL_tier1.png) |1 | high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
19
+[[include:table1_MEF2B.md]]
24 20
25 21
26 22
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MEF2C.md
... ...
@@ -13,10 +13,7 @@ MEF2C is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@arthurGenomewideDiscoverySomatic2018]|
19
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
16
+[[include:table1_MEF2C.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
MET.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_MET.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MFHAS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@sarkozyMutationalLandscapeGray2021]|
16
+[[include:table1_MFHAS1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MGA.md
... ...
@@ -13,10 +13,7 @@ MGA acts as a transcriptional repressor and interacts with MYC, a well-known onc
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017]|
16
+[[include:table1_MGA.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
MGEA5.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_MGEA5.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
MIB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MIB1.md]]
19 17
20 18
21 19
MIR142.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established [@grandeGenomewideDiscoverySomatic2019]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@kwanhianMicroRNA142Mutated202012]|
13
+[[include:table1_MIR142.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
MKI67.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_MKI67.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
MLH1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_MLH1.md]]
19 17
20 18
21 19
MME.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_MME.md]]
18 16
19 17
## Warnings
20 18
MMEL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_MMEL1.md]]
19 17
20 18
21 19
MN1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MN1.md]]
19 17
20 18
21 19
MORC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MORC2.md]]
19 17
20 18
21 19
MPDZ.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_MPDZ.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
MPEG1.md
... ...
@@ -13,10 +13,7 @@ Mutations in MPEG1 have been described in DLBCL[@morinMutationalStructuralAnalys
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @schmitzGeneticsPathogenesisDiffuse2018]|
16
+[[include:table1_MPEG1.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
MPL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MPL.md]]
19 17
20 18
21 19
MRGPRF.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_MRGPRF.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MS4A1.md
... ...
@@ -16,10 +16,7 @@ In relapsed DLBCLs, MS4A1 is sometimes mutated and these mutations have been sho
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mottokIntegrativeGenomicAnalysis2019]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@rushtonGeneticEvolutionaryPatterns2020]|
19
+[[include:table1_MS4A1.md]]
23 20
24 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 22
MSH2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_MSH2.md]]
17 15
18 16
## Warnings
19 17
MSH6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_MSH6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MSL2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
+[[include:table1_MSL2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MSN.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_MSN.md]]
19 17
20 18
21 19
MTMR3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MTMR3.md]]
19 17
20 18
21 19
MTMR8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_MTMR8.md]]
19 17
20 18
21 19
MTOR.md
... ...
@@ -16,10 +16,7 @@ Although mutations in MTOR have been reported in DLBCL and some BL, their role i
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------------------|
21
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017] |
19
+[[include:table1_MTOR.md]]
23 20
24 21
## Warnings
25 22
MYB.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@deschGenotypingCirculatingTumor2020]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC|
14
+[[include:table1_MYB.md]]
18 15
19 16
## Warnings
20 17
MYBPC2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_MYBPC2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MYCBP2.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in FL in 2021 by Hübschmann et al.[
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_MYCBP2.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
MYD88.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@yanBCRTLRSignaling2012]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@ngoOncogenicallyActiveMYD882011]|
17
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established|
13
+[[include:table1_MYD88.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
MYH10.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_MYH10.md]]
17 15
18 16
## Warnings
19 17
MYL7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MYL7.md]]
19 17
20 18
21 19
MYLK.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_MYLK.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
MYO18A.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_MYO18A.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
MYO19.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_MYO19.md]]
19 17
20 18
21 19
MYO1G.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_MYO1G.md]]
19 17
20 18
21 19
MYO5C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MYO5C.md]]
19 17
20 18
21 19
MYOM2.md
... ...
@@ -13,9 +13,7 @@ The prevalence of MYOM2 mutations in DLBCL varies across studies. The role of th
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_MYOM2.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
MYRIP.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_MYRIP.md]]
19 17
20 18
21 19
NANOG.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_NANOG.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NAV1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_NAV1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NBEAL1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
13
+[[include:table1_NBEAL1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NCOA6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_NCOA6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
NCOR1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_NCOR1.md]]
17 15
18 16
## Warnings
19 17
NCOR2.md
... ...
@@ -13,12 +13,7 @@ Mutations in this gene are relatively rare in DLBCL overall but show a pattern o
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@sarkozyMutationalLandscapeGray2021]|
19
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
20
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
21
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established |
16
+[[include:table1_NCOR2.md]]
22 17
23 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 19
NDUFS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NDUFS1.md]]
19 17
20 18
21 19
NEAT1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_NEAT1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NEB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established|
16
+[[include:table1_NEB.md]]
19 17
20 18
21 19
NEK1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_NEK1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
NELL2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NELL2.md]]
19 17
20 18
21 19
NF1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_NF1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NFIB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NFIB.md]]
19 17
20 18
21 19
NFKB2.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_NFKB2.md]]
18 15
19 16
## Warnings
20 17
NFKBIA.md
... ...
@@ -13,11 +13,7 @@ NFKBIA encodes IκBα, an inhibitor of NF-κB, which regulates the NF-κB signal
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wienandGenomicAnalysesFlowsorted2019]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lakeMutationsNFKBIAEncoding2009]|
20
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
16
+[[include:table1_NFKBIA.md]]
21 17
22 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 19
NFKBIE.md
... ...
@@ -14,11 +14,7 @@ NFKBIE encodes IκBε, a negative regulator of NF-κB. Mutations in NFKBIE can d
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@mansouriFrequentNFKBIEDeletions2016]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinGeneticLandscapesRelapsed2016]|
21
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@pararajalingamCodingNoncodingDrivers2020]|
17
+[[include:table1_NFKBIE.md]]
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 20
NFKBIZ.md
... ...
@@ -13,9 +13,7 @@ The NFKBIZ gene is a significant player in NF-κB signaling, with mutations lead
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@morinGeneticLandscapesRelapsed2016]|
16
+[[include:table1_NFKBIZ.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
NFX1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NFX1.md]]
19 17
20 18
21 19
NGFR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NGFR.md]]
19 17
20 18
21 19
NIN.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_NIN.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NIPBL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NIPBL.md]]
19 17
20 18
21 19
NLGN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NLGN2.md]]
19 17
20 18
21 19
NLRP5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_NLRP5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NLRP7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NLRP7.md]]
19 17
20 18
21 19
NLRP8.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
14
+[[include:table1_NLRP8.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
NOA1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_NOA1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
NOL9.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_NOL9.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
NOTCH1.md
... ...
@@ -15,12 +15,7 @@ The relevance of NOTCH1 mutations in various malignancies has been well establis
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
21
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene |
23
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene |
18
+[[include:table1_NOTCH1.md]]
24 19
25 20
## Warnings
26 21
NOTCH2.md
... ...
@@ -11,11 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013]|
18
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@beaLandscapeSomaticMutations2013]|
14
+[[include:table1_NOTCH2.md]]
19 15
20 16
21 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
NOTCH3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_NOTCH3.md]]
19 17
20 18
21 19
NPHP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NPHP1.md]]
19 17
20 18
21 19
NPY2R.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NPY2R.md]]
19 17
20 18
21 19
NR2F2.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2021 by Hübschmann et a
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
18
+[[include:table1_NR2F2.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
NRAS.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_NRAS.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
NRXN2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_NRXN2.md]]
17 15
18 16
## Warnings
19 17
NSD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_NSD1.md]]
19 17
20 18
21 19
NSD2.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established|
16
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@beaLandscapeSomaticMutations2013]|
13
+[[include:table1_NSD2.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
NUP153.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_NUP153.md]]
19 17
20 18
21 19
NUP214.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
+[[include:table1_NUP214.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
ODZ2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
16
+[[include:table1_ODZ2.md]]
19 17
20 18
21 19
ODZ3.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_ODZ3.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
OFD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_OFD1.md]]
19 17
20 18
21 19
OGDHL.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_OGDHL.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ONECUT1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ONECUT1.md]]
19 17
20 18
21 19
OR13C2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|
16
+[[include:table1_OR13C2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
OR6K3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_OR6K3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
OR8H2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_OR8H2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
OSBPL10.md
... ...
@@ -13,9 +13,7 @@ OSBPL10 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ash
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @arthurGenomewideDiscoverySomatic2018; @schmitzGeneticsPathogenesisDiffuse2018]|
16
+[[include:table1_OSBPL10.md]]
19 17
20 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 19
P2RX5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_P2RX5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
P2RY2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
13
+[[include:table1_P2RY2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PABPC1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PABPC1.md]]
19 17
20 18
21 19
PABPC4L.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_PABPC4L.md]]
18 16
19 17
## Warnings
20 18
PACRG.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_PACRG.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PADI1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PADI1.md]]
19 17
20 18
21 19
PAPOLG.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_PAPOLG.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PAPPA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PAPPA2.md]]
19 17
20 18
21 19
PARK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_PARK2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PASD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_PASD1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PASK.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_PASK.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PAX5.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@pasqualucciHypermutationMultipleProtooncogenes2001]|
13
+[[include:table1_PAX5.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PBX1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PBX1.md]]
19 17
20 18
21 19
PC.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
15
+[[include:table1_PC.md]]
18 16
19 17
## Warnings
20 18
PCCB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCCB.md]]
19 17
20 18
21 19
PCDE1C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDE1C.md]]
19 17
20 18
21 19
PCDH7.md
... ...
@@ -13,10 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
19
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@gomezUltraDeepSequencingReveals2023]|
16
+[[include:table1_PCDH7.md]]
20 17
21 18
22 19
PCDHA11.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_PCDHA11.md]]
18 16
19 17
## Warnings
20 18
PCDHB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDHB1.md]]
19 17
20 18
21 19
PCDHB11.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_PCDHB11.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PCDHB15.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDHB15.md]]
19 17
20 18
21 19
PCDHB2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_PCDHB2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PCDHB3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDHB3.md]]
19 17
20 18
21 19
PCDHB5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDHB5.md]]
19 17
20 18
21 19
PCDHB6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_PCDHB6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PCDHGA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PCDHGA2.md]]
19 17
20 18
21 19
PCLO.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
18
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
13
+[[include:table1_PCLO.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
PCSK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_PCSK2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PDCD11.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_PDCD11.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PDE1C.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PDE1C.md]]
19 17
20 18
21 19
PDE4DIP.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_PDE4DIP.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PDGFC.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_PDGFC.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PDGFRA.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PDGFRA.md]]
19 17
20 18
21 19
PDGFRB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PDGFRB.md]]
19 17
20 18
21 19
PDIA2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PDIA2.md]]
19 17
20 18
21 19
PDLIM3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_PDLIM3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PDS5B.md
... ...
@@ -12,10 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|-----------------------------------------|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
18
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established [@hubschmannMutationalMechanismsShaping2021]|
15
+[[include:table1_PDS5B.md]]
19 16
20 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 18
PDZRN3.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_PDZRN3.md]]
18 16
19 17
## Warnings
20 18
PDZRN4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PDZRN4.md]]
19 17
20 18
21 19
PFN1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PFN1.md]]
19 17
20 18
21 19
PGR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PGR.md]]
19 17
20 18
21 19
PHF6.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@thomasGeneticSubgroupsInform2023]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_PHF6.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
PIK3CD.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
13
+[[include:table1_PIK3CD.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PIK3R1.md
... ...
@@ -14,10 +14,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
17
+[[include:table1_PIK3R1.md]]
21 18
22 19
## Warnings
23 20
PIM2.md
... ...
@@ -14,10 +14,7 @@ PIM2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @schmitzGeneticsPathogenesisDiffuse2018; @arthurGenomewideDiscoverySomatic2018]|
17
+[[include:table1_PIM2.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
PKD1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_PKD1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PLA2G4B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PLA2G4B.md]]
19 17
20 18
21 19
PLA2G4D.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]|
16
+[[include:table1_PLA2G4D.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PLCB4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PLCB4.md]]
19 17
20 18
21 19
PLCG2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_PLCG2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PLEKHA7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PLEKHA7.md]]
19 17
20 18
21 19
PLXNB3.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_PLXNB3.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
PMS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_PMS1.md]]
19 17
20 18
21 19
PNLIPRP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PNLIPRP1.md]]
19 17
20 18
21 19
PNPO.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------------------------|
19
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_PNPO.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
PNPT1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PNPT1.md]]
19 17
20 18
21 19
POGZ.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_POGZ.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
POLD3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_POLD3.md]]
19 17
20 18
21 19
POLE.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_POLE.md]]
19 17
20 18
21 19
POLQ.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_POLQ.md]]
19 17
20 18
21 19
POLRMT.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_POLRMT.md]]
17 15
18 16
## Warnings
19 17
POR.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 | Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_POR.md]]
17 15
18 16
## Warnings
19 17
POT1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|------------------------|
16
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_POT1.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
POU2AF1.md
... ...
@@ -13,11 +13,7 @@ POU2AF1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ash
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene, hypermutated[@chapuyMolecularSubtypesDiffuse2018]|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene, hypermutated [@krysiakRecurrentSomaticMutations2017]|
16
+[[include:table1_POU2AF1.md]]
21 17
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
POU2F2.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012; @zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017]|
16
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
13
+[[include:table1_POU2F2.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
PPARGC1A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PPARGC1A.md]]
19 17
20 18
21 19
PPP2R2B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PPP2R2B.md]]
19 17
20 18
21 19
PPP2R5A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_PPP2R5A.md]]
19 17
20 18
21 19
PPP4C.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_PPP4C.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PPP6R2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_PPP6R2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PPWD1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PPWD1.md]]
19 17
20 18
21 19
PRDM1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@pasqualucciInactivationPRDM1BLIMP12006; @zhangGeneticHeterogeneityDiffuse2013; @morinMutationalStructuralAnalysis2013; @reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_PRDM1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PRDM16.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PRDM16.md]]
19 17
20 18
21 19
PREX1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_PREX1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PRKCB.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_PRKCB.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PRKCB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PRKCB1.md]]
19 17
20 18
21 19
PRKCQ.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PRKCQ.md]]
19 17
20 18
21 19
PRKDC.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@schmitzGeneticsPathogenesisDiffuse2018]|
17
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_PRKDC.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
PROS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PROS1.md]]
19 17
20 18
21 19
PRPS1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_PRPS1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PRSS22.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](PRSS22#representative-mutation) in the original primary
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_PRSS22.md]]
21 19
22 20
## Warnings
23 21
PRSS7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PRSS7.md]]
19 17
20 18
21 19
PRUNE2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
+[[include:table1_PRUNE2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
PTCH1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_PTCH1.md]]
19 17
20 18
21 19
PTEN.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@loveGeneticLandscapeMutations2012]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017; @chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_PTEN.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
PTPN1.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@gunawardanaRecurrentSomaticMutations2014]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2-a | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
13
+[[include:table1_PTPN1.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
PTPN14.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PTPN14.md]]
19 17
20 18
21 19
PTPN21.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_PTPN21.md]]
19 17
20 18
21 19
PTPN23.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_PTPN23.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PTPN6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_PTPN6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
PTPRD.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016]|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |low-confidence DLBCL gene|
18
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
13
+[[include:table1_PTPRD.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
PTPRF.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PTPRF.md]]
19 17
20 18
21 19
PTPRK.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_PTPRK.md]]
17 15
18 16
## Warnings
19 17
PTPRN.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_PTPRN.md]]
17 15
18 16
## Warnings
19 17
PTPRT.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PTPRT.md]]
19 17
20 18
21 19
PXDNL.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_PXDNL.md]]
18 16
19 17
## Warnings
20 18
PXK.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_PXK.md]]
19 17
20 18
21 19
PZP.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_PZP.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
RAB3GAP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RAB3GAP1.md]]
19 17
20 18
21 19
RAC2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
14
+[[include:table1_RAC2.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
RAD9A.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_RAD9A.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
RAF1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_RAF1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RANBP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_RANBP2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RANBP6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
13
+[[include:table1_RANBP6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
RAPGEF1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@morinFrequentMutationHistonemodifying2011]|
16
+[[include:table1_RAPGEF1.md]]
19 17
20 18
21 19
RAPGEF2.md
... ...
@@ -13,10 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
19
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established|
16
+[[include:table1_RAPGEF2.md]]
20 17
21 18
22 19
RAPGEF3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RAPGEF3.md]]
19 17
20 18
21 19
RARA.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_RARA.md]]
17 15
18 16
## Warnings
19 17
RASGEF1A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_RASGEF1A.md]]
19 17
20 18
21 19
RB1.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @reddyGeneticFunctionalDrivers2017; @arthurGenomewideDiscoverySomatic2018]|
17
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_RB1.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
RBM15B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RBM15B.md]]
19 17
20 18
21 19
RBM38.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@wienandGenomicAnalysesFlowsorted2019]|
16
+[[include:table1_RBM38.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RBM6.md
... ...
@@ -14,9 +14,7 @@ Mutations in this gene were first described in DLBCL and FL in 2021 by Hübschma
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
17
+[[include:table1_RBM6.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
RBP3.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_RBP3.md]]
17 15
18 16
## Warnings
19 17
RCOR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_RCOR1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RECQL4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RECQL4.md]]
19 17
20 18
21 19
RELN.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@sarkozyMutationalLandscapeGray2021]|
16
+[[include:table1_RELN.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RET.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](RET#representative-mutation) in the original primary da
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_RET.md]]
21 19
22 20
## Warnings
23 21
REV3L.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_REV3L.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
RFC1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RFC1.md]]
19 17
20 18
21 19
RFTN1.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_RFTN1.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
RFX7.md
... ...
@@ -14,10 +14,7 @@ First described as mutated in BL in 2009 by Grande et al.[@grandeGenomewideDisco
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------|
19
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@grandeGenomewideDiscoverySomatic2019]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@arthurGenomewideDiscoverySomatic2018]|
17
+[[include:table1_RFX7.md]]
21 18
22 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 20
RGAG1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_RGAG1.md]]
19 17
20 18
21 19
RGS1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_RGS1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RGS4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_RGS4.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RHEX.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established|
12
+[[include:table1_RHEX.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
RHOA.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@richterRecurrentMutationID32012]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@zhangGeneticHeterogeneityDiffuse2013; @reddyGeneticFunctionalDrivers2017; @chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_RHOA.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
RHOH.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@pasqualucciHypermutationMultipleProtooncogenes2001]|
12
+[[include:table1_RHOH.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
RHPN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RHPN2.md]]
19 17
20 18
21 19
RIF1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RIF1.md]]
19 17
20 18
21 19
RIMS4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RIMS4.md]]
19 17
20 18
21 19
RNF144B.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_RNF144B.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ROBO2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_ROBO2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ROCK1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_ROCK1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
ROR2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ROR2.md]]
19 17
20 18
21 19
RPL10.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_RPL10.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
RPL1L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_RPL1L.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
RPTOR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_RPTOR.md]]
19 17
20 18
21 19
RRAGC.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@reddyGeneticFunctionalDrivers2017;@hubschmannMutationalMechanismsShaping2021]|
16
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@okosunRecurrentMTORC1activatingRRAGC2016] |
13
+[[include:table1_RRAGC.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
RSL1D1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RSL1D1.md]]
19 17
20 18
21 19
RUNDC1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RUNDC1.md]]
19 17
20 18
21 19
RUNX1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_RUNX1.md]]
17 15
18 16
## Warnings
19 17
RYR1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_RYR1.md]]
19 17
20 18
21 19
S1PR1.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|------------------------|
16
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@pararajalingamCodingNoncodingDrivers2020]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png)|2 |relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
14
+[[include:table1_S1PR1.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
S1PR2.md
... ...
@@ -13,12 +13,7 @@ S1PR2 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
19
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@muppidiLossSignalingGa132014]|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011; @lohrDiscoveryPrioritizationSomatic2012; @morinMutationalStructuralAnalysis2013]|
21
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
16
+[[include:table1_S1PR2.md]]
22 17
23 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 19
SAL3.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_SAL3.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SALL3.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|---------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
17
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
14
+[[include:table1_SALL3.md]]
18 15
19 16
## Warnings
20 17
SAMD5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_SAMD5.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SAMD9L.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_SAMD9L.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SAPS2.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
15
+[[include:table1_SAPS2.md]]
18 16
19 17
## Warnings
20 18
SAPS3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SAPS3.md]]
19 17
20 18
21 19
SARM1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_SARM1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SBF1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@loveGeneticLandscapeMutations2012]|
13
+[[include:table1_SBF1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SCG3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_SCG3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SCYL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SCYL1.md]]
19 17
20 18
21 19
SDK2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_SDK2.md]]
19 17
20 18
21 19
SEC14L5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_SEC14L5.md]]
19 17
20 18
21 19
SEL1L3.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
12
+[[include:table1_SEL1L3.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
SEMA3A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SEMA3A.md]]
19 17
20 18
21 19
SEMA3D.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SEMA3D.md]]
19 17
20 18
21 19
SEMA5A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SEMA5A.md]]
19 17
20 18
21 19
SENP7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_SENP7.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SERINC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SERINC2.md]]
19 17
20 18
21 19
SERPINA1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_SERPINA1.md]]
19 17
20 18
21 19
SERPINA9.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_SERPINA9.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SETD1B.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017; @schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_SETD1B.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SETD2.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
18
+[[include:table1_SETD2.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
SETD5.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_SETD5.md]]
17 14
18 15
## Warnings
19 16
SETDB1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_SETDB1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SF3B1.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@reddyGeneticFunctionalDrivers2017; @chapuyMolecularSubtypesDiffuse2018] |
14
+[[include:table1_SF3B1.md]]
18 15
19 16
## Warnings
20 17
SGK1.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@dunsCharacterizationDLBCLPMBL2021]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
17
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene [@morinFrequentMutationHistonemodifying2011; @zhangGeneticHeterogeneityDiffuse2013; @morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_SGK1.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
SH3PXD2B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SH3PXD2B.md]]
19 17
20 18
21 19
SHANK1.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3|Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_SHANK1.md]]
17 15
18 16
## Warnings
19 17
SHMT2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SHMT2.md]]
19 17
20 18
21 19
SHROOM3.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_SHROOM3.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SI.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_SI.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SIAH2.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_SIAH2.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
SIGLEC10.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SIGLEC10.md]]
19 17
20 18
21 19
SIN3A.md
... ...
@@ -11,12 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
17
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@grandeGenomewideDiscoverySomatic2019]|
18
-|![MZL](images/icons/MZL_tier1.png) |1 |high-confidence MZL gene [@rossiCodingGenomeSplenic2012]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@chapuyMolecularSubtypesDiffuse2018; @arthurGenomewideDiscoverySomatic2018]|
14
+[[include:table1_SIN3A.md]]
20 15
21 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 17
SLC16A7.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SLC16A7.md]]
19 17
20 18
21 19
SLC16A8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_SLC16A8.md]]
19 17
20 18
21 19
SLC17A6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_SLC17A6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SLC29A2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3| Retired, Failed QC [@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_SLC29A2.md]]
17 15
18 16
## Warnings
19 17
SLC34A2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_SLC34A2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SLC38A8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_SLC38A8.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SLC4A8.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SLC4A8.md]]
19 17
20 18
21 19
SLC5A1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SLC5A1.md]]
19 17
20 18
21 19
SLC9A5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SLC9A5.md]]
19 17
20 18
21 19
SLITRK6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_SLITRK6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SMARCA1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_SMARCA1.md]]
19 17
20 18
21 19
SMARCA4.md
... ...
@@ -16,13 +16,7 @@ Overall, components of SWI/SNF have been identified as an emerging theme in germ
16 16
17 17
## Relevance tier by entity
18 18
19
-|Entity|Tier|Description |
20
-|:------:|:----:|--------------------------|
21
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
22
-|![BL](images/icons/BL_tier1.png) |1[@dengSMARCA4HaploinsufficientCell2024] |high-confidence BL gene [@richterRecurrentMutationID32012]|
23
-|![DLBCL](images/icons/DLBCL_tier1.png) |1[@dengSMARCA4HaploinsufficientCell2024] |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
24
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@krysiakRecurrentSomaticMutations2017]|
25
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@nadeuGenomicEpigenomicInsights2020]|
19
+[[include:table1_SMARCA4.md]]
26 20
27 21
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
28 22
SMARCB1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@nadeuGenomicEpigenomicInsights2020]|
13
+[[include:table1_SMARCB1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SMC1A.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_SMC1A.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SMEK1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
13
+[[include:table1_SMEK1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SMO.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_SMO.md]]
19 17
20 18
21 19
SNTB2.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_SNTB2.md]]
18 16
19 17
## Warnings
20 18
SOCS1.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@wenigerMutationsTumorSuppressor2006]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011; @lohrDiscoveryPrioritizationSomatic2012; @zhangGeneticHeterogeneityDiffuse2013; @morinMutationalStructuralAnalysis2013]|
18
-|![FL](images/icons/FL_tier1.png) |1 | aSHM target and high-confidence FL gene |
13
+[[include:table1_SOCS1.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
SOS2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_SOS2.md]]
19 17
20 18
21 19
SOX6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SOX6.md]]
19 17
20 18
21 19
SP140.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@beaLandscapeSomaticMutations2013]|
13
+[[include:table1_SP140.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SPEG.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SPEG.md]]
19 17
20 18
21 19
SPEN.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@sarkozyMutationalLandscapeGray2021]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017; @schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_SPEN.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
SPTBN1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SPTBN1.md]]
19 17
20 18
21 19
SRPX.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_SRPX.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SRRM2.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established [@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_SRRM2.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
ST6GAL1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_ST6GAL1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ST8SIA3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ST8SIA3.md]]
19 17
20 18
21 19
STAB2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_STAB2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
STAT3.md
... ...
@@ -12,10 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@ohgamiSTAT3MutationsAre2014]|
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012; @morinFrequentMutationHistonemodifying2011; @reddyGeneticFunctionalDrivers2017]|
15
+[[include:table1_STAT3.md]]
19 16
20 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 18
STAT5B.md
... ...
@@ -15,10 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
21
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
18
+[[include:table1_STAT5B.md]]
22 19
23 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 21
STAT6.md
... ...
@@ -15,12 +15,7 @@ The STAT6 gene, which encodes a transcription factor involved in the JAK-STAT si
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene|
21
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@ritzRecurrentMutationsSTAT62009]|
22
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@yildizActivatingSTAT6Mutations2015]|
23
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@yildizActivatingSTAT6Mutations2015]|
18
+[[include:table1_STAT6.md]]
24 19
25 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
26 21
STXBP5.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_STXBP5.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SULF2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_SULF2.md]]
19 17
20 18
21 19
SWAP70.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
+[[include:table1_SWAP70.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SYK.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_SYK.md]]
17 15
18 16
## Warnings
19 17
SYN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_SYN2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
SYNE1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@nadeuGenomicEpigenomicInsights2020]|
13
+[[include:table1_SYNE1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
SYNGAP1.md
... ...
@@ -15,9 +15,7 @@ Due to [minimal support](SYNGAP1#representative-mutation) in the original primar
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|--------------------------------------|
20
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
18
+[[include:table1_SYNGAP1.md]]
21 19
22 20
## Warnings
23 21
SYPL1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_SYPL1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TAF1.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @reddyGeneticFunctionalDrivers2017; @hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_TAF1.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
TAF1L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TAF1L.md]]
19 17
20 18
21 19
TAF4B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TAF4B.md]]
19 17
20 18
21 19
TAP1.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@schmitzGeneticsPathogenesisDiffuse2018]|
13
+[[include:table1_TAP1.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
TBC1D15.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_TBC1D15.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TBC1D26.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|---------------------------------------|
15
-|![MCL](images/icons/MCL_tier2.png) |2 |relevance in MCL not firmly established[@zhangGenomicLandscapeMantle2014]|
13
+[[include:table1_TBC1D26.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TBC1D3F.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established|
16
+[[include:table1_TBC1D3F.md]]
19 17
20 18
21 19
TBC1D4.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous [@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_TBC1D4.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TBC1D9B.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_TBC1D9B.md]]
17 15
18 16
## Warnings
19 17
TBK1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
+[[include:table1_TBK1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TBL1XR1.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012; @morinMutationalStructuralAnalysis2013]|
18
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
13
+[[include:table1_TBL1XR1.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
TBP.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_TBP.md]]
19 17
20 18
21 19
TCF3.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
17
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene[@schmitzBurkittLymphomaPathogenesis2012]|
14
+[[include:table1_TCF3.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
TCL1A.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![BL](images/icons/BL_tier1.png) |1 | aSHM target and high-confidence BL gene [@grandeGenomewideDiscoverySomatic2019]|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |1 | aSHM target and high-confidence DLBCL gene|
13
+[[include:table1_TCL1A.md]]
17 14
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TCTN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@spinaGeneticsNodalMarginal2016]|
16
+[[include:table1_TCTN2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TECRL.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TECRL.md]]
19 17
20 18
21 19
TERT.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|------------------------|
15
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene[@nadeuGenomicEpigenomicInsights2020]|
13
+[[include:table1_TERT.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TET2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@albuquerqueEnhancingKnowledgeDiscovery2017]|
14
+[[include:table1_TET2.md]]
17 15
18 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 17
TFAP4.md
... ...
@@ -14,9 +14,7 @@ Mutations in BL were first described by Grande et al.[@grandeGenomewideDiscovery
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|-----------------------|
19
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene[@grandeGenomewideDiscoverySomatic2019]|
17
+[[include:table1_TFAP4.md]]
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 20
TGFBR2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_TGFBR2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
THBS4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_THBS4.md]]
19 17
20 18
21 19
TICRR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_TICRR.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TIGD6.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3|Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_TIGD6.md]]
17 15
18 16
## Warnings
19 17
TIMM50.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TIMM50.md]]
19 17
20 18
21 19
TIPARP.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_TIPARP.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TLL2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_TLL2.md]]
19 17
20 18
21 19
TLN1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TLN1.md]]
19 17
20 18
21 19
TLN2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TLN2.md]]
19 17
20 18
21 19
TLR2.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
16
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@beaLandscapeSomaticMutations2013]|
13
+[[include:table1_TLR2.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
TLR4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TLR4.md]]
19 17
20 18
21 19
TMC1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TMC1.md]]
19 17
20 18
21 19
TMEM161A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TMEM161A.md]]
19 17
20 18
21 19
TMEM16E.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TMEM16E.md]]
19 17
20 18
21 19
TMEM30A.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011; @zhangGeneticHeterogeneityDiffuse2013; @morinMutationalStructuralAnalysis2013]|
16
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@morinFrequentMutationHistonemodifying2011]|
13
+[[include:table1_TMEM30A.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
TMEM63A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TMEM63A.md]]
19 17
20 18
21 19
TMSB4X.md
... ...
@@ -14,11 +14,7 @@ TMSB4X is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm
14 14
15 15
## Relevance tier by entity
16 16
17
-|Entity|Tier|Description |
18
-|:------:|:----:|--------------------------------------|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
20
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@zhangGeneticHeterogeneityDiffuse2013; @albuquerqueEnhancingKnowledgeDiscovery2017]|
21
-|![FL](images/icons/FL_tier1.png) |1| aSHM target and high-confidence FL gene |
17
+[[include:table1_TMSB4X.md]]
22 18
23 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 20
TMSL3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_TMSL3.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TNF.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_TNF.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TNFAIP3.md
... ...
@@ -10,12 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@schmitzTNFAIP3A20Tumor2009]|
16
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiAlterationBIRC3Multiple2011]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@compagnoMutationsMultipleGenes2009]|
18
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene |
13
+[[include:table1_TNFAIP3.md]]
19 14
20 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
21 16
TNFRSF14.md
... ...
@@ -12,11 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@spinaGeneticsNodalMarginal2016] |
18
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinFrequentMutationHistonemodifying2011] |
19
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@cheungAcquiredTNFRSF14Mutations2010] |
15
+[[include:table1_TNFRSF14.md]]
20 16
21 17
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 18
TNIP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
+[[include:table1_TNIP1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TNIP2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@vandenbrandRecurrentMutationsGenes2017]|
16
+[[include:table1_TNIP2.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TNPO1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TNPO1.md]]
19 17
20 18
21 19
TNRC6B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_TNRC6B.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TOP2A.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_TOP2A.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TOX.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@reddyGeneticFunctionalDrivers2017; @schmitzGeneticsPathogenesisDiffuse2018; @chapuyMolecularSubtypesDiffuse2018; @hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_TOX.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TP53.md
... ...
@@ -11,14 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------|
16
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiCodingGenomeSplenic2012]|
17
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@tiacciPervasiveMutationsJAKSTAT2018]|
18
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@wildaInactivationARFMDM2p53Pathway2004]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
20
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene [@morinFrequentMutationHistonemodifying2011]|
21
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@beaLandscapeSomaticMutations2013]|
14
+[[include:table1_TP53.md]]
22 15
23 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 17
TPP1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_TPP1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TPR.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TPR.md]]
19 17
20 18
21 19
TPRKB.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TPRKB.md]]
19 17
20 18
21 19
TPST2.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------------------|
16
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@loveGeneticLandscapeMutations2012]|
14
+[[include:table1_TPST2.md]]
17 15
18 16
## Warnings
19 17
TPTE.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established|
16
+[[include:table1_TPTE.md]]
19 17
20 18
21 19
TRAF3.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@ottoGeneticLesionsTRAF32012]|
16
-|![MZL](images/icons/MZL_tier1.png)|1|high-confidence MZL gene[@rossiAlterationBIRC3Multiple2011]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
13
+[[include:table1_TRAF3.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
TRAF6.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_TRAF6.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TRIM2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@novakWholeexomeAnalysisReveals2015]|
16
+[[include:table1_TRIM2.md]]
19 17
20 18
21 19
TRIM37.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TRIM37.md]]
19 17
20 18
21 19
TRIP11.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@reichelFlowSortingExome2015]|
16
+[[include:table1_TRIP11.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TRPM6.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established[@beaLandscapeSomaticMutations2013]|
16
+[[include:table1_TRPM6.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
TRRAP.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |3 |Retired for DLBCL[@zhangGeneticHeterogeneityDiffuse2013]|
13
+[[include:table1_TRRAP.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
TSC2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TSC2.md]]
19 17
20 18
21 19
TSC22D1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_TSC22D1.md]]
19 17
20 18
21 19
TSHZ2.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_TSHZ2.md]]
19 17
20 18
21 19
TTN.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_TTN.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
TYRO3.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_TYRO3.md]]
19 17
20 18
21 19
UBE2A.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene [@lohrDiscoveryPrioritizationSomatic2012; @albuquerqueEnhancingKnowledgeDiscovery2017; @reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_UBE2A.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
UBE2J1.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in DLBCL is tenuous |
12
+[[include:table1_UBE2J1.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
UBR5.md
... ...
@@ -15,11 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
21
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
22
-|![MCL](images/icons/MCL_tier1.png) |1 |high-confidence MCL gene [@pararajalingamCodingNoncodingDrivers2020]|
18
+[[include:table1_UBR5.md]]
23 19
24 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
25 21
UBXN11.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_UBXN11.md]]
19 17
20 18
21 19
UBXN2B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_UBXN2B.md]]
19 17
20 18
21 19
UHRF1BP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@albuquerqueEnhancingKnowledgeDiscovery2017]|
16
+[[include:table1_UHRF1BP1.md]]
19 17
20 18
21 19
UHRF1BP1L.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_UHRF1BP1L.md]]
19 17
20 18
21 19
UNC13B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_UNC13B.md]]
19 17
20 18
21 19
UNC5B.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_UNC5B.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
UNC5C.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |low-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
13
+[[include:table1_UNC5C.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
UNC5D.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|--------------------------|
14
-|![DLBCL](images/icons/DLBCL_tier2.png) | 2 |low-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
12
+[[include:table1_UNC5D.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
UQCRC1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_UQCRC1.md]]
19 17
20 18
21 19
USH2A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@parryWholeExomeSequencing2013]|
16
+[[include:table1_USH2A.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
USP7.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@grandeGenomewideDiscoverySomatic2019]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |2 |low-confidence DLBCL gene[@arthurGenomewideDiscoverySomatic2018]|
13
+[[include:table1_USP7.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
VANGL1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_VANGL1.md]]
19 17
20 18
21 19
VAX1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_VAX1.md]]
19 17
20 18
21 19
VMA21.md
... ...
@@ -9,9 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|-----------------------|
14
-|![FL](images/icons/FL_tier1.png) |1 |high-confidence FL gene[@hubschmannMutationalMechanismsShaping2021]|
12
+[[include:table1_VMA21.md]]
15 13
16 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
17 15
VMP1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@mottokIntegrativeGenomicAnalysis2019]|
16
+[[include:table1_VMP1.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
VPS13A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_VPS13A.md]]
19 17
20 18
21 19
VPS13B.md
... ...
@@ -9,10 +9,7 @@ nocite: |
9 9
10 10
## Relevance tier by entity
11 11
12
-|Entity|Tier|Description |
13
-|:------:|:----:|--------------------------|
14
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene|
15
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@lohrDiscoveryPrioritizationSomatic2012]|
12
+[[include:table1_VPS13B.md]]
16 13
17 14
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 15
VWA7.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_VWA7.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
WAC.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@rossiCodingGenomeSplenic2012]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_WAC.md]]
18 15
19 16
## Warnings
20 17
WDFY3.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@morinMutationalStructuralAnalysis2013]|
13
+[[include:table1_WDFY3.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
WDR65.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WDR65.md]]
19 17
20 18
21 19
WDR66.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WDR66.md]]
19 17
20 18
21 19
WDR67.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WDR67.md]]
19 17
20 18
21 19
WDR7.md
... ...
@@ -12,9 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|--------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |3 |Retired, Failed QC[@paneaWholeGenomeLandscape2019]|
15
+[[include:table1_WDR7.md]]
18 16
19 17
## Warnings
20 18
WDR87.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@dunsCharacterizationDLBCLPMBL2021]|
16
+[[include:table1_WDR87.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
WDR90.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_WDR90.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
WEE1.md
... ...
@@ -13,10 +13,7 @@ WEE1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ashm)
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------|
18
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
19
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene[@schmitzGeneticsPathogenesisDiffuse2018]|
16
+[[include:table1_WEE1.md]]
20 17
21 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
22 19
WHAMM.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_WHAMM.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
WIF1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WIF1.md]]
19 17
20 18
21 19
WNK1.md
... ...
@@ -10,11 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![MZL](images/icons/MZL_tier2.png)|2|relevance in MZL not firmly established[@jalladesExomeSequencingIdentifies2017]|
16
-|![BL](images/icons/BL_tier1.png) |1 |high-confidence BL gene [@thomasGeneticSubgroupsInform2023]|
17
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@hubschmannMutationalMechanismsShaping2021]|
13
+[[include:table1_WNK1.md]]
18 14
19 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 16
WNK2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@paneaWholeGenomeLandscape2019]|
13
+[[include:table1_WNK2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
WNK4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WNK4.md]]
19 17
20 18
21 19
WT1.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_WT1.md]]
19 17
20 18
21 19
XDH.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_XDH.md]]
19 17
20 18
21 19
XIRP2.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![FL](images/icons/FL_tier2.png) |2 |relevance in FL not firmly established[@russler-germainMutationsAssociatedProgression2023]|
13
+[[include:table1_XIRP2.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
XPO1.md
... ...
@@ -11,10 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|--------------------------|
16
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@jardinRecurrentMutationsExportin2016]|
17
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@mareschalWholeExomeSequencing2016; @reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_XPO1.md]]
18 15
19 16
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
20 17
YY1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017; @chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_YY1.md]]
16 14
17 15
## Warnings
18 16
YY1AP1.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@schmitzBurkittLymphomaPathogenesis2012]|
13
+[[include:table1_YY1AP1.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ZAN.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_ZAN.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ZBTB7A.md
... ...
@@ -12,10 +12,7 @@ nocite: |
12 12
13 13
## Relevance tier by entity
14 14
15
-|Entity|Tier|Description |
16
-|:------:|:----:|-----------------------------------------|
17
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established [@burkhardtClinicalRelevanceMolecular2022]|
18
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
15
+[[include:table1_ZBTB7A.md]]
19 16
20 17
## Warnings
21 18
ZCCHC11.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![PMBL](images/icons/PMBL_tier2.png)|2|relevance in PMBL/cHL/GZL not firmly established[@tiacciPervasiveMutationsJAKSTAT2018]|
16
+[[include:table1_ZCCHC11.md]]
19 17
20 18
21 19
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
ZEB2.md
... ...
@@ -15,9 +15,7 @@ Mutations in this gene were first described in DLBCL in 2013[@zhangGeneticHetero
15 15
16 16
## Relevance tier by entity
17 17
18
-|Entity|Tier|Description |
19
-|:------:|:----:|-----------------------------------------|
20
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
18
+[[include:table1_ZEB2.md]]
21 19
22 20
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
23 21
ZFAT.md
... ...
@@ -11,9 +11,7 @@ nocite: |
11 11
12 12
## Relevance tier by entity
13 13
14
-|Entity|Tier|Description |
15
-|:------:|:----:|-----------------------------------------|
16
-|![DLBCL](images/icons/DLBCL_tier2.png) |3 |Retired, Failed QC[@reddyGeneticFunctionalDrivers2017]|
14
+[[include:table1_ZFAT.md]]
17 15
18 16
## Warnings
19 17
ZFP36L1.md
... ...
@@ -13,12 +13,7 @@ ZFP36L1 is one of [a number of genes](https://github.com/morinlab/LLMPP/wiki/ash
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description |
17
-|:------:|:----:|--------------------------------------|
18
-|![MCL](images/icons/MCL_tier2.png)|2|relevance in MCL not firmly established|
19
-|![PMBL](images/icons/PMBL_tier1.png)|1|high-confidence PMBL/cHL/GZL gene[@reichelFlowSortingExome2015]|
20
-|![BL](images/icons/BL_tier2.png) |2 | aSHM target; Although recurrent, the relevance of mutations in BL is tenuous [@paneaWholeGenomeLandscape2019]|
21
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 | aSHM target and high-confidence DLBCL gene [@morinFrequentMutationHistonemodifying2011]|
16
+[[include:table1_ZFP36L1.md]]
22 17
23 18
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
24 19
ZFX.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_ZFX.md]]
16 14
17 15
## Warnings
18 16
ZIC4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZIC4.md]]
19 17
20 18
21 19
ZMYM4.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_ZMYM4.md]]
19 17
20 18
21 19
ZNF354A.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF354A.md]]
19 17
20 18
21 19
ZNF366.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF366.md]]
19 17
20 18
21 19
ZNF385B.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@lohrDiscoveryPrioritizationSomatic2012]|
16
+[[include:table1_ZNF385B.md]]
19 17
20 18
21 19
ZNF423.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|-----------------------------------------|
15
-|![DLBCL](images/icons/DLBCL_tier2.png) |2 |relevance in DLBCL not firmly established[@chapuyMolecularSubtypesDiffuse2018]|
13
+[[include:table1_ZNF423.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16
ZNF439.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF439.md]]
19 17
20 18
21 19
ZNF474.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF474.md]]
19 17
20 18
21 19
ZNF521.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier2.png)|2|relevance in DLBCL not firmly established[@pasqualucciAnalysisCodingGenome2011]|
16
+[[include:table1_ZNF521.md]]
19 17
20 18
21 19
ZNF608.md
... ...
@@ -10,10 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------|
15
-|![FL](images/icons/FL_tier2.png)|2|relevance in FL not firmly established[@krysiakRecurrentSomaticMutations2017]|
16
-|![DLBCL](images/icons/DLBCL_tier1.png) |1 |high-confidence DLBCL gene[@morinMutationalStructuralAnalysis2013; @reddyGeneticFunctionalDrivers2017]|
13
+[[include:table1_ZNF608.md]]
17 14
18 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
19 16
ZNF700.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF700.md]]
19 17
20 18
21 19
ZNF790.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@zhangGeneticHeterogeneityDiffuse2013]|
16
+[[include:table1_ZNF790.md]]
19 17
20 18
21 19
ZNF814.md
... ...
@@ -13,9 +13,7 @@ nocite: |
13 13
14 14
## Relevance tier by entity
15 15
16
-|Entity|Tier|Description|
17
-|:------:|:----:|--------------------------------------|
18
-|![DLBCL](images/icons/DLBCL_tier3.png)|3|relevance in DLBCL not firmly established[@fanComprehensiveCharacterizationDriver2020]|
16
+[[include:table1_ZNF814.md]]
19 17
20 18
21 19
ZNF85.md
... ...
@@ -10,9 +10,7 @@ nocite: |
10 10
11 11
## Relevance tier by entity
12 12
13
-|Entity|Tier|Description |
14
-|:------:|:----:|--------------------------------------|
15
-|![BL](images/icons/BL_tier2.png) |2 |relevance in BL not firmly established[@burkhardtClinicalRelevanceMolecular2022]|
13
+[[include:table1_ZNF85.md]]
16 14
17 15
## Mutation incidence in large patient cohorts (GAMBL reanalysis)
18 16